DERMAPLIQ

,

Clerapliq – RGTA® mimic heparan sulfate in regenerative medicine

Clerapliq -RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients

Denis Barritault & Marie Gilbert-Sirieix & Kim Lee Rice & Fernando Siñeriz & Dulce Papy-Garcia & Christophe Baudouin & Pascal Desgranges & Gilbert Zakine & Jean-Louis Saffar8 & Johan van Neck

Abstract The importance of extracellular matrix (ECM) in- tegrity in maintaining normal tissue function is highlighted by numerous pathologies and situations of acute and chronic in- jury associated with dysregulation or destruction of ECM components. Heparan sulfate (HS) is a key component of the ECM, where it fulfils important functions associated with tissue homeostasis. Its degradation following tissue injury dis- rupts this delicate equilibrium and may impair the wound healing process. ReGeneraTing Agents (RGTA®s) are poly- saccharides specifically designed to replace degraded HS in injured tissues. The unique properties of RGTA® (resistance to degradation, binding and protection of ECM structural and signaling proteins, like HS) permit the reconstruction of the ECM, restoring both structural and biochemical functions to this essential substrate, and facilitating the processes of tissue repair and regeneration. Here, we review 25 years of research surrounding this HS mimic, supporting the mode of action, pre-clinical studies and therapeutic efficacy of RGTA® in the clinic, and discuss the potential of RGTA® in new branches of regenerative medicine.

Link : Here

Dermapliq – RGTA Improves Healing Time and Quality in Hairless Rats

Dermapliq – Regenerating matrix-based therapy for chronic wound healing

Suzanne L Groah, Alexander Libin, Miriam Spungen, Kim-Loan Nguyen, Earthaleen Woods, Marjan Nabili, Jessica Ramella-Roman, Denis Barritault

The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan sulphate mimetic (CACIPLIQ20) improves chronic wound healing. The design of this article is a prospective within- subject study. The setting was an urban hospital. Patients were 16 African-American individuals (mean age 42 years) with 22 wounds (mean duration 2·5 years) because of either pressure, diabetic, vascular or burn wounds. Two partic- ipants each were lost to follow-up or removed because of poor compliance, resulting in 18 wounds analysed. Sterile gauze was soaked with CACIPLIQ20 saline solution, placed on the wound for 5 min, then removed twice weekly for 4 weeks. Wounds were otherwise treated according to the standard of care. Twenty-two percent of wounds fully healed during the treatment period. Wounds showed a 15·2–18·1% decrease in wound size as measured by the vision engineering research group (VERG) digital wound measurement system and total PUSH scores, respectively, at 4 weeks (P = 0·014 and P = 0·003). At 8 weeks there was an 18–26% reduction in wound size (P = 0·04) in the remaining patients. Wound-related pain measured by the visual analogue pain scale and the wound pain scale declined 60% (P = 0·024) and 70% (P = 0·001), respectively. Patient and clinician satisfaction remained positive throughout the treatment period. It is concluded that treatment with CACIPLIQ20 significantly improved wound- related pain and may facilitate wound healing. Patient and clinician satisfaction remained high throughout the trial.

Link : Here

Regenerating matrix-based therapy for chronic wound healing

Dermapliq – Regenerating matrix-based therapy for chronic wound healing

Suzanne L Groah, Alexander Libin, Miriam Spungen, Kim-Loan Nguyen, Earthaleen Woods, Marjan Nabili, Jessica Ramella-Roman, Denis Barritault

The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan sulphate mimetic (CACIPLIQ20) improves chronic wound healing. The design of this article is a prospective within- subject study. The setting was an urban hospital. Patients were 16 African-American individuals (mean age 42 years) with 22 wounds (mean duration 2·5 years) because of either pressure, diabetic, vascular or burn wounds. Two partic- ipants each were lost to follow-up or removed because of poor compliance, resulting in 18 wounds analysed. Sterile gauze was soaked with CACIPLIQ20 saline solution, placed on the wound for 5 min, then removed twice weekly for 4 weeks. Wounds were otherwise treated according to the standard of care. Twenty-two percent of wounds fully healed during the treatment period. Wounds showed a 15·2–18·1% decrease in wound size as measured by the vision engineering research group (VERG) digital wound measurement system and total PUSH scores, respectively, at 4 weeks (P = 0·014 and P = 0·003). At 8 weeks there was an 18–26% reduction in wound size (P = 0·04) in the remaining patients. Wound-related pain measured by the visual analogue pain scale and the wound pain scale declined 60% (P = 0·024) and 70% (P = 0·001), respectively. Patient and clinician satisfaction remained positive throughout the treatment period. It is concluded that treatment with CACIPLIQ20 significantly improved wound- related pain and may facilitate wound healing. Patient and clinician satisfaction remained high throughout the trial.

Link : Here